Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): Three- and 4-year results - 09/08/11
, Emory Menefee, PhD b, Matilde Sanchez, PhD c, Keith D. Kaufman, MD d
Reprint requests: Vera H. Price, MD, FRCPC, Department of Dermatology, University of California, San Francisco, 350 Parnassus Ave, Suite 404, San Francisco, CA 94117.San Francisco and Richmond, California; and Rahway, New Jersey
Abstract |
Background |
We previously reported the effects of finasteride on scalp hair weight and count over a 2-year period in men with androgenetic alopecia (AGA).
Objective |
Our purpose was to evaluate the effects of finasteride on hair weight and count over 4 years in men with AGA.
Methods |
Men with AGA were randomized to receive finasteride (1 mg/d) or placebo for 192 weeks. Results of the second (weeks 96-144) and third (weeks 144-192) extension periods are reported.
Results |
Finasteride increased hair weight at 144 and 192 weeks (week 192: finasteride, 21.6% increase from baseline; placebo, 24.5% decrease from baseline; net increase in hair weight for finasteride vs placebo = 46.0%, P < .001). Hair count also increased with finasteride at 144 and 192 weeks (week 192: finasteride, 7.2% increase from baseline; placebo, 13.0% decrease from baseline; net increase in hair count for finasteride vs placebo = 20.3%, P < .05). Finasteride was generally well tolerated.
Limitations |
Because this study was extended from its original 48-week duration to nearly 4 years, the sample size available for analysis decreased with time.
Conclusion |
Long-term finasteride treatment led to sustained improvement in hair weight compared with placebo. Hair weight increased to a larger extent than hair count, implying that factors other than the number of hairs, such as increased growth rate (length) and thickness of hairs, contribute to the beneficial effects of finasteride in treated men.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: Merck Research Laboratories, Merck & Co, Inc. Disclosure: Merck & Co, Inc. manufactures and markets finasteride. Dr Menefee was a paid consultant for Merck & Co, Inc. Drs Sanchez and Kaufman are employees of and hold stock in Merck & Co., Inc. |
Vol 55 - N° 1
P. 71-74 - juillet 2006 Retour au numéro
Article précédent
- Eczema herpeticum patients needed for referral
- Tuchinda C, Srivannaboon S, Lim HW. Photoprotection by window glass, automobile glass, and sunglasses. J Am Acad Dermatol 2006;54:845-54 (May).
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?